Advertisement

Topics

EIGR Soars On Progeria Deal, BOLD Investors Emboldened, BDSI's Cash Strengthens

01:39 EDT 18 May 2018 | RTTNews

Eiger Pharmaceutical Inc. (EIGR) has expanded its licensing agreement with Merck to include rights to develop experimental drug Lonafarnib for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria), a rare and fatal genetic condition characterized by accelerated aging in children.

Original Article: EIGR Soars On Progeria Deal, BOLD Investors Emboldened, BDSI's Cash Strengthens

NEXT ARTICLE

More From BioPortfolio on "EIGR Soars On Progeria Deal, BOLD Investors Emboldened, BDSI's Cash Strengthens"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...